EPS growth is an important number as it indicates the future prospects of ADMA Biologics Inc. It is typically displayed as a percentage and called the EPS growth rate, which at this time is hard to estimate, but revenue growth has been -35.00 % over the last twelve months. EPS growth is a vital measure of execution of the strategy for ADMA Biologics Inc since it indicates how well the business is allocating resources to benefit shareholders.



ADMA Biologics Inc is part of the healthcare sector and trades as part of the biotechnology industry. The company CEO is Adam S. Grossman. ADMA Biologics Inc is a biopharmaceutical company. The company develops and manufactures specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases.

Previous Intraday Performance:

The ADMA shares had a previous change of -1.18% which opened at 3.40 and closed at 3.35. It moved to an intraday high of 3.41 and a low of 3.25.

SeekingAlpha:  ADMA Bio up 7% on submission of responses to Bivigam CRL

Historical Performance:

Over the last five trading days, ADMA shares returned 6.69% and in the past 30 trading days it returned -37.96%. Over three months, it changed -37.50%. In one year it has changed -6.42% and within that year its 52-week high was 6.96 and its 52-week low was 2.08. ADMA stock is 61.06% above its 52 Week Low.

Our calculations result in a 200 day moving average of 5.16 and a 50 day moving average of 4.45. Right now, ADMA stock is trading -35.04% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  ADMA Bio up 7% on submission of responses to Bivigam CRL

Liquidity:

The company has a market cap of $155.3m with 46.4m shares outstanding and a float of 46.1m shares. Trading volume was 179,535 shares and has experienced an average volume of 306,101 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

The last annual reported EPS for ADMA Biologics Inc was -1.89 which ended on 31st of December 2017. Based on 4 analyst estimates, the consensus EPS for the next quarter is -0.30.

Below was the last reported quarterly earnings per share:
09-30-2018:  -0.33
06-30-2018:  -0.35
03-31-2018:  -0.35
12-31-2017:  -0.24

Indicators Also to Watch:

Based on the latest filings, there is 0.50% of insider ownership and 62.90% of institutional ownership. Short-interest was 0, which was 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio was 0.00.



I calculated the beta to be 2.96

PR Newswire:  BMO Financial Group Announces New Financial Crimes Unit to be Headed by Larry Zelvin

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -241.79%, return on assets is -67.75%, price-to-sales is 12.26 and price-to-book is 4.17.

Company Score Card:

Results are out of six:
 5  : Growth Expectations Result
 5  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 2  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here